M. Zheng, C. Hou, R. Wang, Yingying Wei, Jilu Zhang, Xin Li, Guojiang Chen, G. Han, B. Shen, Yan Li, Yuanfang Ma, He Xiao
{"title":"Therapeutic effects and possible mechanisms of sirolimus on nephritic mice with chronic rejection","authors":"M. Zheng, C. Hou, R. Wang, Yingying Wei, Jilu Zhang, Xin Li, Guojiang Chen, G. Han, B. Shen, Yan Li, Yuanfang Ma, He Xiao","doi":"10.13220/J.CNKI.JIPR.2014.03.014","DOIUrl":null,"url":null,"abstract":"Objective To explore the therapeutic effects of sirolimus on nephritic mice with chronic rejection,and the possible mechanisms. Methods B6D2F1mice transplanted with cell mixture of spleen,thymus,and lymph nodes from DBA /2 spleen,thymus,and lymph nodes cell mixture were used to construct murine model with chronic rejection,and the transplanted mice were randomly divided into two groups. Mice in the sirolimus-treated group were given sirolimus orally in a dose of 1 mg /( kg·d) for 12 consecutive weeks,while mice in the control group were administered with equal amounts of olive oil. Nephritis in mice was confirmed by urine protein determination and histopathological analysis. Enzyme immunoassay was used to detect the serum levels of anti-DNA antibodies including anti-ds DNA IgG,anti-ds DNA IgG1,anti-ds DNA IgG2a,anti-ss DNA IgG,anti-ss DNA IgG1,and anti-ss DNA IgG 2a. Real-time PCR analysis was conducted to evaluate the gene expression of interleukin-6( IL-6),tumor necrosis factor-α( TNF-α),interferon-γ( IFN-γ),interleukin-1β( IL-1β),monocyte chemoattractant protein 1( MCP-1),regulated upon activation normal T cell expressed and secreted( RANTES),B lymphocyte chemoattractant( BLC),transforming growth factor β1( TGF-β1),and collgen I. The proportion and activation of T and B lymphocytes in peripheral blood or spleen were determined by flow cytometric analysis.Results At the end of observation period,the incidence of nephritis in mice treated with sirolimus was significantly lower than that of mice treated with olive oil( P 0. 05). Histopathological evaluation of kidney specimen showed evident vascular intimal hyperplasia and mononuclear cell infiltration in control group. In contrast,no obvious kidney lesions was observed in sirolimus-treated mice. Furthermore,the levels of anti-DNA antibodies and the transcriptional expression of lupus IL-6,TNF-α,IFN-γ,IL-1β,MCP-1,RANTES,BLC,TGF-β1,and collgen I were significantly down-regulated in sirolimus-treated group as compared with control group. Flow cytometric analysis indicated that both of the proportion of activated /memory T cells in peripheral blood and the expression level of surface activation markers on T and B lymphocytes in spleen were significantly decreased in mice exposed to sirolimus as compared with those exposed to olive oil( P 0. 05). On the other hand,the proportion of CD4+FOXP3+regulatory T cells in spleen was significantly upregulated in sirolimus-treated group as compared with control group. Conclusion Sirolimus may inhibit the proliferation and activation of effector cells and downregulate the expression of chemokines and inflammatory factors through up-regulation of CD4+FOXP3+T cells,thus effectively ameliorating the progression of nephritis in mice.","PeriodicalId":16265,"journal":{"name":"国际药学研究杂志","volume":"41 1","pages":"335-341"},"PeriodicalIF":0.0000,"publicationDate":"2014-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"国际药学研究杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.13220/J.CNKI.JIPR.2014.03.014","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
Abstract
Objective To explore the therapeutic effects of sirolimus on nephritic mice with chronic rejection,and the possible mechanisms. Methods B6D2F1mice transplanted with cell mixture of spleen,thymus,and lymph nodes from DBA /2 spleen,thymus,and lymph nodes cell mixture were used to construct murine model with chronic rejection,and the transplanted mice were randomly divided into two groups. Mice in the sirolimus-treated group were given sirolimus orally in a dose of 1 mg /( kg·d) for 12 consecutive weeks,while mice in the control group were administered with equal amounts of olive oil. Nephritis in mice was confirmed by urine protein determination and histopathological analysis. Enzyme immunoassay was used to detect the serum levels of anti-DNA antibodies including anti-ds DNA IgG,anti-ds DNA IgG1,anti-ds DNA IgG2a,anti-ss DNA IgG,anti-ss DNA IgG1,and anti-ss DNA IgG 2a. Real-time PCR analysis was conducted to evaluate the gene expression of interleukin-6( IL-6),tumor necrosis factor-α( TNF-α),interferon-γ( IFN-γ),interleukin-1β( IL-1β),monocyte chemoattractant protein 1( MCP-1),regulated upon activation normal T cell expressed and secreted( RANTES),B lymphocyte chemoattractant( BLC),transforming growth factor β1( TGF-β1),and collgen I. The proportion and activation of T and B lymphocytes in peripheral blood or spleen were determined by flow cytometric analysis.Results At the end of observation period,the incidence of nephritis in mice treated with sirolimus was significantly lower than that of mice treated with olive oil( P 0. 05). Histopathological evaluation of kidney specimen showed evident vascular intimal hyperplasia and mononuclear cell infiltration in control group. In contrast,no obvious kidney lesions was observed in sirolimus-treated mice. Furthermore,the levels of anti-DNA antibodies and the transcriptional expression of lupus IL-6,TNF-α,IFN-γ,IL-1β,MCP-1,RANTES,BLC,TGF-β1,and collgen I were significantly down-regulated in sirolimus-treated group as compared with control group. Flow cytometric analysis indicated that both of the proportion of activated /memory T cells in peripheral blood and the expression level of surface activation markers on T and B lymphocytes in spleen were significantly decreased in mice exposed to sirolimus as compared with those exposed to olive oil( P 0. 05). On the other hand,the proportion of CD4+FOXP3+regulatory T cells in spleen was significantly upregulated in sirolimus-treated group as compared with control group. Conclusion Sirolimus may inhibit the proliferation and activation of effector cells and downregulate the expression of chemokines and inflammatory factors through up-regulation of CD4+FOXP3+T cells,thus effectively ameliorating the progression of nephritis in mice.
目的探讨西罗莫司对肾病小鼠慢性排斥反应的治疗作用及其可能的机制。方法采用DBA /2脾、胸腺、淋巴结细胞混合物移植b6d2f1小鼠,构建慢性排斥反应小鼠模型,将移植小鼠随机分为两组。西罗莫司治疗组小鼠口服西罗莫司,剂量为1 mg /(kg·d),连续12周,对照组小鼠给予等量橄榄油。尿蛋白测定和组织病理学分析证实小鼠肾炎。采用酶免疫分析法检测血清抗DNA抗体水平,包括抗ds DNA IgG、抗ds DNA IgG1、抗ds DNA IgG2a、抗ss DNA IgG、抗ss DNA IgG1和抗ss DNA IgG2a。采用Real-time PCR方法检测小鼠外周血或脾脏T淋巴细胞中活化调控的白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、干扰素-γ(IFN-γ)、白细胞介素-1β(IL-1β)、单核细胞趋化蛋白1(MCP-1)、B淋巴细胞趋化因子(BLC)、转化生长因子β1(TGF-β1)、胶原i的基因表达情况,采用流式细胞术检测外周血或脾脏中T淋巴细胞和B淋巴细胞的比例和活化情况。结果观察期末,西罗莫司组小鼠肾炎发生率明显低于橄榄油组(P < 0.05)。05). 肾标本病理组织学检查显示,对照组血管内膜明显增生,单核细胞浸润。相比之下,西罗莫司治疗的小鼠未观察到明显的肾脏损伤。西罗莫司治疗组抗dna抗体水平及狼疮IL-6、TNF-α、IFN-γ、IL-1β、MCP-1、RANTES、BLC、TGF-β1、colgen I转录表达均较对照组显著下调。流式细胞术分析表明,与橄榄油相比,西罗莫司暴露小鼠外周血中活化/记忆T细胞的比例和脾脏中T淋巴细胞和B淋巴细胞表面活化标志物的表达水平显著降低(P < 0.05)。05). 另一方面,西罗莫司治疗组脾脏CD4+FOXP3+调节性T细胞比例较对照组显著上调。结论西罗莫司可能通过上调CD4+FOXP3+T细胞,抑制效应细胞的增殖和活化,下调趋化因子和炎症因子的表达,从而有效改善小鼠肾炎的进展。
国际药学研究杂志Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
自引率
0.00%
发文量
10973
期刊介绍:
An intentional Journal which is published quarterly in English. Journal publishes papers, review articles, and short communications dealing with drug controlled release systems, pharmacodynamics, pharmacokinetics, pharmacogenomics, biopharmaceutics, drug and prodrug design, pharmaceutical analysis, drug stability, quality control, pharmaceutical engineering and materials science.Pharmaceutical Chemistry, Pharmaceutical Technology, pharmacognosy, natural product research, pharmaceutics, novel drug delivery, pharmaceutical & medicinal chemistry, computational chemistry and molecular drug design, pharmacology, pharmaceutical analysis, pharmacy practice, clinical and hospital pharmacy etc. IJPR would take much care in making your article published without much delay with your kind cooperation. IJPR hopes that Researchers, Research scholars, Academician, Industrialists etc. would make use of this research publications for the development of pharmaceutical science and technology.